Selecting Differentially Expressed Genes from Microarray Experiments by Pepe, Margaret S. et al.
UW Biostatistics Working Paper Series
1-27-2003
Selecting Differentially Expressed Genes from
Microarray Experiments
Margaret S. Pepe
University of Washington, mspepe@u.washington.edu
Gary M. Longton
Fred Hutchinson Cancer Research Center, glongton@fhcrc.org
Garnet L. Anderson
Fred Hutchinson Cancer Research Center, garnet@whi.org
Michel Schummer
Institute for Systems Biology
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors
Suggested Citation
Pepe, Margaret S.; Longton, Gary M.; Anderson, Garnet L.; and Schummer, Michel, "Selecting Differentially Expressed Genes from
Microarray Experiments" ( January 2003). UW Biostatistics Working Paper Series. Working Paper 184.
http://biostats.bepress.com/uwbiostat/paper184
CONFIDENTIAL 
Selecting Differentially Expressed Genes from Microarray Experiments 
 
Margaret Sullivan Pepe,1,2 Gary Longton,2 Garnet L. Anderson,2 and Michel Schummer3 
1Department of Biostatistics, University of Washington 
Seattle, Washington 98195-7232, U.S.A 
2Division of Public Health Sciences, Fred Hutchinson Cancer Research Center 
Seattle, Washington 98109-1024, U.S.A. 
3Institute for Systems Biology, Seattle, Washington 98105-6099, U.S.A. 
*email: mspepe@u.washington.edu 
 
SUMMARY. High throughput technologies, such as gene expression arrays and protein 
mass spectrometry, allow one to simultaneously evaluate thousands of potential 
biomarkers that distinguish different tissue types. Of particular interest here is cancer 
versus normal organ tissues. We consider statistical methods to rank genes (or proteins) 
in regards to differential expression between tissues. Various statistical measures are 
considered and we argue that two measures related to the Receiver Operating 
Characteristic Curve are particularly suitable for this purpose. We also propose that 
sampling variability in the gene rankings be quantified and suggest using the ‘selection 
probability function,’ the probability distribution of rankings for each gene. This is 
estimated via the bootstrap. A real data set derived from gene expression arrays of 23 
normal and 30 ovarian cancer tissues are analyzed. Simulation studies are also used to 
assess the relative performance of different statistical gene ranking measures and our 
quantification of sampling variability. Our approach leads naturally to a procedure for 
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sample size calculations appropriate for exploratory studies that seek to identify 
differentially expressed genes. 
 
KEY WORDS: Classification; Discrimination; Exploratory analysis; Genomics; Prediction; 
Proteomics; ROC curves. 
 
1. Introduction 
The development of microarrays that provide simultaneous evaluation of mRNA 
expression levels for thousands of genes is one of the exciting new advances in modern 
medical research. It promises to identify disease at its most basic biological level, namely 
at that of the genes. The implications for medicine are considerable (The Chipping 
Forecast, 1999). Insights into genetic alterations caused by disease can lead to new 
therapeutic strategies. Genetic alterations that precede disease can be targets for disease 
prevention strategies. The research community can expect insights into the etiology of 
disease and pathways involved in its progression, that may well revolutionize medical 
practice. 
 
There are new statistical challenges posed by data from microarray experiments, due 
primarily to the exploratory nature of experiments and the huge numbers of genes under 
investigation. It must also be recognized that different sorts of questions are addressed 
with microarray experiments and that the appropriate statistical approach depends, of 
course, on the question of interest (Dudoit et al, 2000). Categories of objectives 
pertaining to experiments that include multiple tissue types (e.g. cancer versus non-
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cancer tissue) include: i) selection of genes that are differentially expressed in different 
known classes of tissue; (ii) identification of a minimal combination of genes that 
provides discrimination between known tissue types; (iii) identification of groups of 
genes whose expression levels are correlated; and (iv) new classifications of tissue types 
defined by genes whose expression levels are related.  Statistical techniques such as 
regression methods and discriminant analyses have been adapted for (ii) (Dudoit et al, 
2000), whereas clustering techniques are more appropriate for (iii) and (iv) (Tibshirani et 
al, 2000, Hastie et al, 2000, Lazzeroni and Owen, 2002, Van Der Laan and Bryan, 2001). 
In this paper we consider statistical methods for objective (i), which, at first glance, 
seems to be the most straight-forward.  
 
The particular application that motivated our work concerns the search for biomarkers of 
ovarian cancer that could be used in population screening. Ovarian tissue from 30 
subjects with cancer and 23 subjects without cancer were analyzed for mRNA expression 
using glass arrays spotted for 1536 gene clones. The data, Y , for the gig th gene clone in 
the ith tissue sample, is a measure of the mRNA expression of the gth gene in that tissue 
relative to a control tissue, with a common control employed for all experiments. We 
refer to Dudoit et al. (2002) and Newton et al. (2000) for a simple summary of this 
technology and a technical explanation for how Y  is calculated. Schummer et al. (1999) 
describe their data processing algorithms that are similar to those used to arrive at the 
relative expression values in the ovarian cancer study.  Using standard terminology for 
these experiments, Y  is the logarithm of the  ratio of the intensities of the red to green 
ig
ig
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fluorescent dyes, where green dye is used for the common control and red is used for the 
experimental tissue. 
 
The scientific objective is to identify genes that are differentially expressed in ovarian 
cancer tissue compared with normal ovarian tissue. Ovarian tissue cannot of course be 
used directly for population screening. However, if a gene is found that is expressed 
differentially in cancer tissue, then the corresponding protein product (or an antibody to 
it) may be detectable in blood or urine and could be the basis for a population screening 
test. We refer to Pepe et al (2001) for discussion of the phases of biomarker development 
from the initial exploratory phase that we discuss here to its application in population 
screening programs. In general, scientists are more interested in identifying genes that are 
over-expressed rather than under-expressed in cancer screening research. This is  because 
detecting the presence of a new aberrant protein in blood is a potentially easier task than 
detecting the reduced level of a normal protein, particularly if that protein is also 
produced by normal organ tissue in the body of the patient with cancer. Therefore in this 
paper we focus on detection of over-expressed genes although adaptation of the methods 
to detection of under-expressed genes is obvious. 
 
There are many genes over-expressed in cancer tissue that cannot lead to screening 
markers. For example, genes that relate simply to inflammation or growth are not 
candidates because those processes also occur naturally in the body. Clinical assays for 
some gene products may be too difficult to develop for technical reasons. Therefore we 
need to select a sizeable number of over-expressed genes in order to arrive at a subset that 
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might have potential for screening. For the initial selection, we will include multiple 
genes that are redundant in the sense that they identify the same cancer samples so that if 
one gene proves useless for biomarker development we can still pursue another that could 
identify those same cancers. 
 
The experimental data are used to rank candidate genes according to some statistical 
measure characterizing differential expression. In section 2 we discuss the choice of 
statistical measure. A method for quantifying the degree of confidence in the ranking of a 
gene provided by the data is proposed is section 3. This acknowledges the finite number 
of tissues examined, variability across tissues and the large number of genes investigated, 
all of which contribute to uncertainty in the ranking of the genes. Application to the 
ovarian cancer data in section 4 illustrates the approach. One approach to computing 
sample sizes in these exploratory studies is suggested in section 5. Some further remarks 
about experimental design are made in section 6. We close with some thoughts on further 
extensions of our proposed methods. 
 
2. Characterizing Interesting Differential Expression 
 
2.1 Measures of Discrimination 
 
At each gene, data are available for nD cancer tissues and nC normal tissues. 
, 1, ...,
.
, 1, ...,
D
gi D
C
gj C
Y i n
Y j n
=
=
       
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To say that there is differential expression at gene g is to say that the distribution of DgY  
 
is different from that for CgY . What sorts of differences are of particular interest? Figure 1 
displays some hypothetical distributions that we use for discussion. Although we depict 
the distribution of CgY
C
 as a standard normal distribution, this is a matter of convenience 
only and our discussion is more general in that we do not assume any particular 
distribution for gY . Our discussion here only concerns the separation between the 
distributions for CgY  and 
D
gY . Note that there always exists a transformation so that 
C
gY  is 
standard normal and the view in Figure 1 is on this scale. Since most of the procedures 
we will discuss are rank based, knowledge of the specific transformation is not necessary. 
Moreover, our discussion about separation in this section does not require knowledge of 
the transformation either.  
 
The ideal situation is represented in the top panel where there is almost complete 
separation between the distributions. In this case the relative expression level of gene g is 
an ideal candidate marker for cancer because the values are completely different in 
cancer tissue from those in normal tissue. There is a threshold value that allows one to 
classify cancer versus normal tissue with almost 100% accuracy. 
 
Consider now settings where the distributions overlap. We contend that for cancer 
screening, the separation in panel II is of more practical interest than that in panel III. The 
marker clearly distinguishes a subset of cancers from normals in II, whereas in panel III 
marker values for cancer tissues are entirely within the range of those for non-cancer 
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tissues. Looking ahead to population screening and assuming that gene expression 
translates roughly into protein expression, in panel II there is a threshold for the screening 
test that provides detection of about 30% of cancers while falsely identifying only 1% of 
non-cancers as screen positive. In screening it is important to keep false positive rates 
extremely low because even a small false positive rate translates into large numbers of 
people being subjected to diagnostic procedures that are costly and invasive. Using a 
similar threshold in panel III corresponding to the 1% false positive rate, detects only 2% 
of cancers because the distributions overlap over the whole normative range. 
 
We suggest that statistical measures of discrimination between the distribution of DgY  and 
C
gY  focus on separation at and beyond upper quantiles of the normative range. Figure 2 
shows receiver operating characteristic (ROC) curves that characterize separations 
between distributions. Each point on the ROC curve, (t,ROC(t)), corresponds to a 
different threshold u, and by definition t = P[ CgY ≥u], and ROC(t)=P[
D
gY ≥u]. The ROC 
curve can be thought of as a plot of the true versus false positive rates associated with all 
possible thresholds for classifying a tissue as cancerous based on the relative expression 
level gY  (Pepe, 2000). Because low values of t correspond to high quantiles of 
C
gY , our 
suggestion is to focus on the ROC curve at low values of . t
 
Two summary measures of discrimination that are commonly used in ROC analysis are: 
 
  0 0( ) [ (1 )]
D C
gROC t P Y y t= ≥ −
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 and 
 
( ) 00
0
( ) .
t
pAUC t ROC t dt= ∫  
 
where t  is some small false positive rate and 0 0(1 )
Cy t−  is the quantile in the upper tail 
of the normative range corresponding to . The measure ROC (  is easily conceived of 
by non-statisticians, as the proportion of cancer tissues with expression levels above the  
 quantile of normal tissues. The partial area under the curve, pAUC , in effect 
averages this proportion across values of t
0t 0 )t
0(1 t− ) 0( )t
0t<  (McClish, 1989).  If two curves have the 
same value of ROC ( , the curve with larger pAUC (  would indicate better 
separation at that gene because for some values of t
0 )t 0 )t
0t< , ROC (  must be higher for that 
gene. 
)t
 
The ROC (  or pAUC  statistic calculated for the three settings of Figure 1, ranks 
biomarker II better than biomarker III for small values of t  ( t ≤0.10). On the other 
hand, other classic measures of discrimination such as the two-sample t-statistic or the 
Mann-Whitney U statistic(equivalently the Wilcoxon statistic) rank biomarker III better 
than biomarker II. We regard this as a serious weakness of those statistics for our 
application. We also see from Figure 2 that all of these statistics rank biomarker I as the 
0 )t 0( )t
0 0
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best, regardless of , and indeed any reasonable statistic should because biomarker I is 
almost perfect.  
0t
 
How should one choose t ? Ideally the choice of t  will depend on false positive rates 
that are acceptable in practice, and  could be chosen as the maximally acceptable one. 
The magnitudes of false positive rates that are acceptable will vary with the application 
since they depend on the costs and consequences of the errors. Very small t  are in 
general required for cancer screening. However, with small numbers of tissue samples, 
estimation of pAUC (  or ROC  at very small  will not be possible. Thus in our 
application we chose  to be small, but large enough that the estimates of ROC  and 
pAUC (  were reasonably  precise for our purposes. Further research into appropriate 
choices for t  in large and small sample studies would be worthwhile. 
0
)
0
t
0t
0( )
0
0t
0t
t 0
0( )t
0 )t
0
 
We suggest that empirical estimates of ROC (  and pAUC  be used to rank genes 
for differential expression in cancer versus normal tissue. Other measures of 
discrimination that we calculate for comparison are: (i) Zstat, the standardized difference 
in means, i.e., the two-sample t-statistic and (ii) AUC, the area under the entire ROC 
curve 
0 )t 0( )t
1
0
( ) .AUC ROC t dt= ∫  
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Interestingly the empirical AUC is equal to the numerator of the Mann-Whitney U-
statistic, [ ] /D Cgi gj D
i j
I Y Y n n≥∑ ∑ C , and hence equivalent to the Wilcoxon ranksum 
statistic for comparing the distribution of DgY  and 
C
gY . It can be interpreted as an estimate 
of  (Bamber, 1975). Each of ROC , pAUC  and AUC are 
distribution free rank statistics whereas Zstat depends on the underlying probability 
distributions for 
D C
g gY ≥ 
D
P Y 0( )t 0( )t
gY
C and gY . 
 
2.2  Illustration 
 
To illustrate our ideas we consider a small dataset comprising the first 100 genes in our 
ovarian cancer dataset. Table 1 displays the top 10 ranking genes in order when ranked 
according to the different statistical measures. Later we will return to the larger dataset. 
For illustration purposes, we chose a smaller set here because this provided substantial 
variation in the discrimination capacities of the top 10 genes while the top 10 genes from 
the  larger pool of genes were less varied. 
 
Turning  to Table 1 we see that to a large extent the same genes were identified by all 
discrimination measures, although the order of ranking differed. Consider, however, 
genes 5 and 97 for which raw data and ROC curves are displayed in Figure 3. The Mann-
Whitney U-statistic (AUC) ranked these genes very similarly, as the 6th and 8th, 
respectively. On the other hand, the pAUC statistic ranked them quite differently as the 
3rd and 31st ranking genes, respectively. The raw data and the ROC curves indicate that 
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indeed for gene 5 more of the cancer tissues are above the bulk of the normative range 
than is the case for gene 97. The pAUC statistic picks up on this fact and gives it a far 
higher rank than it gives gene 97. It suggests to these authors that gene 5 should receive 
higher priority for biomarker development than gene 97. 
 
Insert Table 1 
 
2.3 Additional steps for selection. 
 
The main point we wish to make in this section is that careful consideration of the 
statistical measure used to rank genes in regards to differential expression is warranted in 
applications. In disease screening, ROC or pAUC measures are proposed. The ranking is 
of course only one step in the process of selecting genes for further study. One will 
investigate the actual separation achieved between the distributions of DgY  and 
C
gY  for 
genes that rank well. ROC curves such as shown in Figure 3b should be considered in 
this evaluation because they display the separation achieved on a scale that is relevant to 
the problem and that allows for direct comparisons between genes. It is more difficult to 
compare genes using frequency distributions of the raw expression data (Figure 3a). 
 
The next step towards selecting genes for further experimental work is to investigate 
what is already known about the function of the genes that appear to have promising 
differential expression. Libraries of information are available from the public and private 
domains. Genes may be eliminated from further investigation for a variety of reasons 
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related to their known function or prior experience with assay development. Investigators 
then select some set of genes for further investigation. The number depends on multiple 
factors, not the least of which is the resources available for experimental work. 
 
In this paper we focus on the initial step in the gene selection process, namely the ranking 
step that orders genes in regards to a statistical measure of differential expression. In 
section 3 we discuss the sampling variability in the rank ordering. Related to this, in 
section 5 we propose that the achievement of adequate rank ordering be a basis for 
choosing sample sizes in these studies. In particular we propose that the study design 
should ensure that genes with promising differential expression should rank high and 
therefore be drawn to the attention of the investigators. 
 
3. Assessing Variability 
 
3.1 The probability of gene selection. 
 
The relative rankings of genes is the primary outcome of the study. However, the 
rankings are subject to sampling variability. How should this variability be 
acknowledged? Standard errors or p-values don’t seem to be directly relevant to the task 
because the stated objective is neither to estimate parameters nor to test hypotheses. 
Rather, the task is to rank genes and to select the top genes for further study. Therefore 
we propose the following quantity to quantify our degree of confidence in choosing the 
gth gene among the top k. 
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  Pg(k) = P[gene g ranked in the top k] 
   = P[Rank (g) ≤ k] 
 
The value of  may be of particular interest for k equal to a predetermined number 
of genes to be selected (10 in the small illustration). However, the whole survivor 
function can be considered, { ( , and this gives a more full description of 
sampling variability in the ranking. Various factors contribute to the variability in 
Rank(g): (i) the number of cancer tissues and normal tissues studied,  and ; (ii) the 
extent and type of differential expression of the g
( )gP k
( )P k
),  1gP k k ≥ }
Dn Cn
th gene; (iii) the number of genes in the 
selection pool, which we denote by N; (iv) the differential expression of genes other than 
the gth gene; and not least, (v) the algorithm or statistical measure used to rank genes. The 
quantity, , will be affected by all of these factors. g
 
Intuitively, as sample sizes increase, the  function will tend to 0 or 1 for 
differentially expressed genes according to whether the true asymptotic discriminating 
measure for the g
( )gP k
th gene ranks below  or not. Genes that in truth are very highly 
discriminatory will certainly have high ranks even in experiments with small sample sizes 
and  will be close to 1. This may be reduced by chance if there is a large number of 
competing genes and in particular if a substantial number of competing genes also exhibit 
differential expression. Observe that at the opposite extreme, if no genes are differentially 
expressed, then . 
k
( )gP k
( ) /gP k k N=
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 The selection probabilities, , as we call them, can be estimated by the bootstrap 
with the resampling unit being at the tissue level. Thus, when a tissue is included in the 
bootstrap sample, the entire vector of data relating to all genes for that tissue is entered 
into the bootstrapped dataset, and genes are ranked within the dataset according to the 
statistical measure chosen. The bootstrapping therefore acknowledges the complex 
correlations between genes. 
( )gP k
 
All of our statistical measures but Zstat are rank statistics. Tied data points influence the 
distribution of rank statistics and we note that tied data points ensue with simple 
resampling of observed data. However, real data, such as the original dataset, do not have 
ties because gY  is measured on a continuous scale. Thus, we modified the bootstrapping 
to randomly break ties by adding miniscule random noise (jitter) to the expression levels. 
This was done in an effort to make the bootstrap distribution of the rank statistics more 
reflective of the actual distribution across different realizations of the experiment. 
 
 
3.2  Illustration 
 
Returning to the small illustration described earlier, Table 1 shows  based on 200 
bootstrapped samples for each gene ranked in the top 10. Thus if the strategy of the 
experiment is to select the top 10 genes ranked on the basis of ROC(0.1), we are highly 
confident (  about the selection of genes 93, 76, 65 and 42. However, we 
(10)gP
(10) 90%)gP >
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estimate that, due to sampling variability, genes 35, 23 and 52 have 60%≤  chance of 
ranking in the top 10 if the experiment were repeated. 
0)
k =
 
A comparison of the two estimators of , with and without jitter in the bootstrap 
sample, suggested that they are quite similar. That is, we arrive at the same conclusions 
about  for the rank-based measures if the data are jittered or not. Thus tied 
datapoints in the bootstrap samples do not appear to affect the  estimates 
substantially. 
(10)gP
(10)gP
(1gP
 
3.3  Simulation 
 
As a simple example we simulated data on 2000 genes for equal numbers of cancers and 
normal tissues. Of the 2000 genes, 95% were configured to be non-informative in the 
sense that DgY  and 
C
gY  had the same distributions, namely standard normal (without loss 
of generality). For 100 genes the distributions were normal with mean 1 and standard 
deviation 2 for cancer tissues and standard normal for non-cancer tissues. For an 
informative gene therefore, the area under the corresponding ROC curve was 
67.012/)01(( 22 +−Φ ) =  (Reiser and Guttman, 1986). Data for different genes were 
generated independently. We set the number of genes to be selected at . Table 2 
panel A shows the proportions of informative markers selected averaged across 100 
simulation studies. That is, it shows P[Rank(g)≤k│g is an informative gene]. 
100
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Insert table 2 
 
The results suggest that the top 100 genes consist primarily of informative genes even 
with relatively small sample sizes. An informative gene has a 68% chance of being in the 
top 100 ranked on the basis of the pAUC(0.2) statistic when 30 samples are analyzed, 15 
cancer and 15 normal tissues. The chance reaches 91% when a total of 35 cancer and 35 
normals are evaluated. 
 
In this particular example, (setting A of Table 2), the pAUC statistic was most effective 
at selecting informative genes. Interestingly it outperformed the full area under the curve 
the AUC statistic. That is, focusing on differences between the normal and cancer tissues 
only in the upper end of the normative range, yielded a better selection algorithm. This 
will not always be the case. In another set of simulations (also shown in Table 2) where 
informative genes had a mean 1 and standard deviation 1 in cancer tissues compared with 
standard normal in non-cancer tissues, the AUC statistic performed better.  
 
These simulations assume statistical independence of genes and hence are unlikely to 
reflect real data. In practice one might find that subsets of informative genes are 
correlated statistically, and likewise subsets of uninformative genes are correlated. 
Intuition suggests that this would lead to higher selection probabilities for informative 
genes than those in Table 2 because correlated genes will behave as a unit and reduce 
variability compared with the setting where all genes are independent. We will return to 
simulation studies later when we consider sample size calculations. 
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 4. Analysis of the Full Ovarian Cancer Dataset 
 
The 1536 genes spotted on the glass arrays were ranked according to each of the 
discriminatory statistics defined above. Sixty-five genes were ranked in the top 100 by all 
4 ranking statistics while 16 genes were selected among the top 100 by only one of the 
statistics (7 by ROC (0.10), 9 by pAUC (0.10), 0 by AUC and 0 by Zstat only). 
 
The stability of their selection, quantified by  Pg(100), was estimated with 200 bootstrap 
samples. Figure 4 displays the results. The selection probabilities for the AUC and Zstat 
statistics are overall higher than those for the pAUC (0.10) and ROC (0.10) statistics. 
This presumably indicates less variability in the statistics that use more of data, namely 
AUC and Zstat. The selection algorithms based on them therefore are less variable and 
more reproducible across experiments. However, we saw earlier (Table 2) that this does 
not necessarily induce higher sensitivity to differential expression and in particular to the 
sorts of differential expression of most interest to biologists. 
 
Another display of the resampling results, specifically for the pAUC (0.1) statistic, is 
shown in Figure 5. For each gene selected we calculated its ranking in each bootstrap 
sample. Its 80th and 90th percentile across the bootstrap samples is shown. We observe for 
example that gene 1483, which ranked best in the original dataset, ranked at or above 14 
in 90% of the resampled datasets and at or above 8 in 80% of the resampled datasets. 
Gene 65, which ranked 50th in the original dataset, had ranks of 148 and 115 at its 90th 
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and 80th bootstrap percentiles, respectively. We see that for all genes ranked in the top 24, 
their rankings were better than 100 in at least 90% of the bootstrap samples. Thus, we 
have high confidence in the good ranking of these genes, in the sense that it is unlikely to 
be attributable to sampling variability. On the other hand, all of the genes that ranked 
worse than 63rd in the original data were at the 150th rank or worse in at least 10% of 
bootstrap samples, and 15/37 (41%) had 90th percentiles above 200. 
 
Let’s briefly consider the biological relevance of the highest ranking genes. The top 10 
ranking clones for the pAUC(0.1) statistic are SPINT2 (2 clones), TACSTD1, HE4, 
Oviductal glycoprotein, Keratin 8, Argininosuccinate synthetase (ASS), 2 ESTs, and a 
novel gene. Of the six genes with known function, five are tumor-related: SPINT2 is 
expressed in colorectal cancer (Kataoka et al., 2000); TACSTD1, an adenocarcinoma-
associated antigen, is currently being used in a clinical trial as a target in the treatment of 
gastro-intestinal carcinomas (Staib et al., 2001); HE4 is a potential ovarian cancer marker 
(Schummer et al., 1999), which is currently being evaluated in a serum assay 
(unpublished results); oviductal glycoprotein has a role in fertilization (Verhage et al., 
1997) and was found to be expressed at higher levels in ovarian carcinomas (unpublished 
results); and Keratin 8 expression is associated with cervical cancer progression (Smedts 
et al., 1990). Moreover, one of the two EST-related clones is homologous to a putative 
integral membrane transporter protein discovered in hepatocellular carcinoma (NCBI 
website http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=retrieve&db=Nucleotide 
&list_uids=7320864&dopt=GenBank). 
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With five of six top-ranking genes known to be related to cancer, our biologist colleagues 
are motivated to study further the remaining 3 genes with unknown function. They 
suspect that those genes may be tumor-related as well. This of course remains to be seen. 
 
Of the top 10 genes selected according to the pAUC(.1) statistic, 6 were also ranked in 
the top 10 by the AUC statistic. The 4 additional genes ranked in the top 10 by AUC 
included one with unknown function, one that relates to a brain protein not found in 
normal ovary, one “housekeeping genes” involved in glycolysis and one (IFI27) that has 
been found to be overexpressed in breast carcinomas. The last two were ranked 28 and 
30, respectively, with the pAUC(.1) statistic having values that were approximately 64% 
of the ideal value of 0.1. In contrast the 9th  and 10th  ranking genes according to the 
pAUC(.1) algorithm were 80% of the ideal value. 
 
5. Sample Size Calculations 
 
Gene expression microarray experiments are expensive. Therefore in practice sample 
sizes tend to be small. Our simulation study and analysis of the ovarian cancer dataset 
nevertheless, suggested that an informative analysis, properly accounting for sampling 
variability, can be based on experiments with relatively small sample sizes. This initially 
seemed surprising to us, but in retrospect it is intuitively reasonable. Informative genes 
will show themselves to be so even with small sample sizes. 
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What advice can the statistician offer for choices of sample sizes in exploratory gene 
expression studies? Since the task is to select informative genes from the pool of genes 
studied, the criterion for choosing sample sizes should be that they be large enough to 
ensure that informative genes have a high chance of being selected for further study on 
the basis of data from the experiment. Again, traditional notions of basing sample size 
calculations on hypothesis tests or on precision of estimators seem inappropriate. 
 
Suppose that resources exist such that the top ranked  genes will be considered for 
further study, , say. The sample size might be driven by the requirement that an 
informative gene, ranking in truth in the top  genes (
0k
1k
0 100k =
1k 30 = say), has a probability of 
at least β  of being ranked in the top  in the experiment. That is, the investigator 
suspects that a gene that ranks in the top k
0k
1 will be of interest and wants to be assured that 
such a gene will be identified in the experiment. Therefore, one might choose  and 
so that  
Dn
cn
 β=≤≤=∈ ])(TrueRank)(Rank[)( 1010 kgkgPkkPg  
where True Rank(g) is the ranking of gene g according to the ranking statistic chosen, if 
an infinite number of tissue samples were studied, D cn n= = ∞
( )gP k
. This probability is 
related to the selection probability  defined earlier. However, here instead of 
quantifying confidence in observed results, it now quantifies the power of the experiment 
to select a gene that in truth is a high ranking gene. Like  it depends on the size and 
( )gP k
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contents of the pool of genes considered, the ranking statistic used and importantly on  
and . 
Dn
cn
n
 
To calculate  we suggest that a simulation study be performed. In fact the 
simulation study described in section 3.3 was our first attempt at this. In that setting we 
calculated  for various sample sizes and showed that even with a total 
sample size of 30, , the study design had a power β = 68% assuming that 
the pAUC (0.1) ranking statistic was used for analysis. The data generating mechanism in 
that simulation, however, is very simple and is not based on a theoretically justifiable 
model. Sample size calculations cannot be used for practical application without such 
justification. Unfortunately, it is extremely unlikely that one can ever stipulate a 
simulation model for gene expression array data that is based on adequate biological 
theory and knowledge of laboratory processes.  
0 1( |gP k k∈
(100 | 100)g ∈
D cn n
)
P
15= =
 
Ideally a set of pilot data would be available upon which to base a simulation. To 
illustrate, suppose that the ovarian cancer data represents a dataset from a pilot study. We 
based a second simulation study on these data. Specifically we resampled with 
replacement the entire data vector of gene expressions for n  cancer tissues and  
normal tissues from the original dataset and determined P
*
D
*
cn
g(k0│∈k1). Various sample 
sizes,  and  were considered. That is, the distributions of observed data were 
regarded as the population distributions for cancers and normals and we randomly 
selected from those (infinite) populations in order to simulate data for the planned 
*
D
*
cn
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experiments. (In this sense bootstrapping can be considered as a simulation.) Table 3 
displays  for various choices of sample sizes. We see that a gene that in 
truth ranks in the top 10 according to the pAUC (0.1) measure is almost certainly selected 
with data from a study involving as few as 30 tissues, if the selection criterion is that its 
pAUC (0.1) statistic ranks in the top 100 in the study. A gene, truly in the top 50 is likely 
to be selected (β=91%) from a study using 25 cancer and 25 non-cancer tissues. 
1(100 | )gP ∈
0( |gP k ∈
1k
∪
k
)
 
The power , 1k , quantifies how likely a gene randomly selected from the top  
is likely to be ranked in the top . Table 3 also displays which is the 
probability that all 
1k
0k
*
Cn
0( |gP k k∪
0k
* * 50D Cn n
 truly top-ranking genes will rank in the top  when the 
experiment involving n  and  tissues is performed. These probabilities are much 
lower because the criterion to be met is more stringent. In order that all top 30 genes be 
likely to be selected it appears that at least 100 tissues 
*
D
= =  should be studied 
(Pg(100│ 30)=84%). 
1)
 
In these simulations we only considered equal numbers of cases and controls. Unequal 
sample sizes could be chosen. It would be interesting to see if, in general, relatively more 
cases than controls are desirable and how this should in general relate to the relative 
variability of gene expressions in cases versus controls. Another aspect that we feel 
should be explored further relates to the likely over-optimism of the pilot data that we use 
for simulation. Efron and Tibshirani (1994, section 25.5) suggest some caution about 
plugging in parameters from a pilot study for power calculations and their concerns apply 
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here too. One could add noise to the observed data in the simulations for more 
conservative sample size calculations. 
 
6. Additional Design and Data Analysis Considerations 
 
 
We have considered only the comparative design where assays for both the normal 
tissues and cancer tissues are performed, each using a common control tissue. Thus a 
sample of relative expression values are obtained for both the normals and the cancers, 
represented by { }, 1, ,Dig DY i n= … , and { }, 1, ,Cjg CY j n= …  , respectively. In this design 
the distribution of DgY  can be compared with that of
C
gY , the latter being the appropriate 
reference distribution. 
 
An alternative design frequently cited in the statistical literature (Van Der Laan and 
Bryan (2001)) entails using a non-cancer tissue as a control within the assay for a cancer 
tissue. The data at gene g from such an experiment can be represented as 
{ , 1, ,ig D}Z i = … n where igZ  is the expression in the cancer tissue relative to the normal 
control transformed to a log scale. Typically the mean of the distribution of gZ  is 
compared with 0, the null value if expression at the gene g is the same on average in 
cancer and normal tissue.  
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We have argued in section 2 that the mean difference { } { }D Cg gE Y Y E Z− =
D
g   is only 
one summary of the separation between the distributions of gY  and 
C
gY , and that in 
many cases alternative summary measures are more relevant. Unfortunately summary 
measures, such as pAUC, are not identifiable from the distribution of gZ . Indeed we 
believe that the two distributions for DgY  and 
C
gY , respectively, or at least their ROC 
curve should be generated by an experiment in order to adequately assess differential 
expression. Unfortunately they simply cannot be reconstructed from the single 
distribution of the composite variable gZ . Clearly many different pairs of random 
variables ( ,  can give rise to a single composite )D Cg gY Y
D C
g g gZ Y Y= − .  
 
In summary, for the type of application we consider in this paper, we prefer the design 
that yields relative expression levels for both normals and cases instead of just the 
composite gZ . This design allows a full and flexible comparison of the two distributions, 
that for normal tissues yielding a reference distribution against which the cancer tissue 
distribution can be compared. Such is not achieved with the design that evaluates normals 
only within the assay for the cancer tissue. 
 
7. Concluding Remarks 
 
In this paper we have considered the identification of a subset of genes that are 
differentially expressed between two tissue types from a large pool of candidate genes. 
The same statistical problem arises in experiments involving other recently developed 
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high throughput technologies. For example, protein mass spectrometry can be used to 
identify a set of proteins differentially expressed from amongst a large set of candidate 
proteins. Large arrays of tumor antigens are used to select a subset to which antibodies 
are differentially present in subjects with and without cancer. The concept of ranking 
genes using a statistical measure of discrimination between tissues, applies equally well 
to proteins in protein spectrometry and to antigens in tumor immunogenicity experiments. 
Thus, our methods will also be useful in these settings. 
 
We have emphasized that investigators must carefully choose the statistical measure for 
ranking the genes so that it fits the purpose of the experiment. For disease screening we 
have argued that biomarkers must be highly specific. This could be argued for other 
applications too, such as in the identification of treatment targets. Statistical measures 
such as the pAUC or ROC statistics are appealing when specificity is important. 
Dudoit et al (2002) use Zstat, the standardized difference in means, to rank genes. Efron 
et al (2000) also use a difference in means with a somewhat different standardization. 
Their rationale for using these measures over others was not discussed. One feature of 
those measures is that they depend on the absolute values of 
0( )t 0( )t
gY , whereas the empirical 
ROC statistics do not since they are rank statistics. This presumably infers robustness on 
the ROC statistics but at the expense of disallowing the magnitudes of relative expression 
to influence the relative ordering of genes. Whether or not the magnitude of gY  should 
influence the gene rankings over and above the separation between the probability 
distributions of DgY  and 
C
gY , is a debatable point since magnitude of expression does not 
translate directly into biological effect in the body. Another feature of the pAUC  and 0( )t
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ROC  statistics is that they are not influenced by variability in the measurement of Y0( )t g 
at the lower end of the scale, at values below the (1-t0) quantile of CgY .   
 
We have suggested the selection probability, , to quantify sampling variability and 
confidence in the gene ranking, and as the basis for sample size calculations. Dudoit et al 
(2000) use p-values for a related purpose. However, we find the interpretation of  
more compelling given the exploratory nature of the study. The purpose is not to test a 
null hypothesis about equal distributions of gene expression versus unequal distributions. 
More importantly, the objective is to rank genes according to the extent of differential 
expression. Although the measures used by Dudoit et al (2000) and by Newton et al 
(2000) are statistics for testing a null hypothesis, they are used more in the same spirit as 
we use statistics, namely to rank genes according to the extent of differential expression. 
Efron et al (2000) consider two probabilities: a p-value, Prob {data at gene g | null 
hypothesis of equal expression}, and a Bayesian probability, Prob {gene g affected | data 
at gene g} = 1-P {equal expression | data at gene g}. Again, since many genes will be 
differentially expressed, probabilities relating to the null state of equal expression seem 
less compelling than ranking the extent of differential expression amongst the genes. 
Moreover, Efron et al (2000) use the probabilities to rank the genes, whereas we use the 
selection probabilities only to quantify sampling variability in the rankings. 
( )gP k
( )gP k
 
Our selection probabilities are more closely related in this regard to the ‘single gene 
probabilities’ proposed by Van der Laan and Bryan (2001). The single gene probabilities 
are used to quantify sampling variability in a gene clustering algorithm, and are estimated 
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by a parametric bootstrap approach. Kerr and Churchill (2001) also assess reliability of 
clustering algorithms with the bootstrap. Our selection probabilities quantify sampling 
variability in a gene ranking algorithm, and are estimated with a non-parametric bootstrap 
procedure. Since the bootstrap provides consistent estimates of the distributions of the 
vectors { 1 , ,
D B
NY } and {Y
C… 1 , ,C NY }, and for any given g, PY… g(k) is a  function of these 
distributions it seems intuitive that the bootstrap estimate of Pg(k) will be consistent. 
However, it is likely that bootstrap or any data-based estimates of  will be 
correlated with the data-based ordering of the gene. This correlation implies that if 
attention is restricted to a subset of genes that are observed to rank high say, then as a 
group their estimated selection probabilities will tend to be biased upwards. Efforts to 
reduce this bias would be worthwhile. 
( )gP k
 
The initial motivation for our research was to develop a strategy for sample size 
calculations. The strategy we propose is based on selection probabilities for informative 
genes, and is implemented with bootstrap simulation studies using pilot data. A similar 
strategy could be used for calculating sample sizes in studies that have the determination 
of gene clusters as the ultimate purpose. The single gene probabilities of Van der Laan 
and Bryan (2001) or some related construct could take the place of the selection 
probabilities in that sort of application. 
 
Laboratory techniques for measuring gene expression with microarrays are certainly 
imperfect. Moreover, data processing procedures for calculating the relative expression 
values from the raw images data are evolving. The variability and biases in the derived 
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values will surely impact on the gene rankings observed. It would be interesting to 
determine the extent of these impacts and if the use of ROC statistics can mitigate some 
of these problems because they are rank based. Hopefully, laboratory and data processing 
procedures will improve in the future, to alleviate related statistical concerns. 
 
Although the identification of differentially expressed genes is the first objective, it is not 
the only objective of an exploratory gene expression study. In cancer research, it is 
recognized that cancer is a heterogeneous disease and that different unidentified subtypes 
may be characterized by unique sets of overexpressed genes. Thus, if a single gene 
doesn’t completely discriminate cancer from non-cancer it may be possible that a small 
set of genes each flagging one subtype will. Statistical methods to identify such minimal 
subsets are needed. Ranking of different subsets of genes might draw on ideas presented 
here. In addition, the identifications of clusters of genes, that is, genes that are over- or 
underexpressed in the same cancer tissues would be of interest. Biological insights into 
the pathways and pathogenesis of cancer would likely result. Some modifications of the 
plaid models (Lazzeroni and Owen, 2002) to include a baseline reference group of tissues 
(non-cancer in our case) might be useful for this purpose. 
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Figure Legends 
 
Figure 1. Hypothetical distributions for gene expression data showing different sorts of 
separations between cancer tissue and normal tissue. 
 
Figure 2. Receiver operating characteristic curves corresponding to pairs of distributions 
shown in Figure 1. 
 
Figure 3(a). Frequency distributions and (b)ROC curves corresponding to gene 5 and 97 
in the ovarian cancer data set. 
 
Figure 4. (a) Violin plots (Hintze and Nelson, 1998) of selection probabilities for the top 
100 ranked genes in the ovarian cancer datasets using 4 different ranking 
statistics. Probability estimates are based on 200 bootstrap samples. The 
median is indicated by a short horizontal line, the first to third interquartile 
range by the narrow shaded box, and a vertical line extends to the upper and 
lower adjacent values. The surrounding violin shell consists of mirrored local 
kernal density estimates of the distribution. The y-axis is labeled at the 
minimum, median, and maximum values. 
(b) A comparison of the selection probabilities for the AUC statistic and the 
pAUC (0.1) statistic. 
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Figure 5. Gene rank percentiles (90th and 80th) in the bootstrap distribution for the ovarian 
cancer data set. Shown are results for the top ranked 100 genes. 200 bootstrap 
samples were drawn with the sampling unit being tissue. 
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Table 1. 
Gene number, selection probability Pg(10), and value of the discriminatory measure for the top 10 ranking genes among the first 100 
genes in the ovarian cancer dataset. 
ROC(.10) pAUC(.10) AUC Z-stat 
rank             
                
gene Pg(10) statistic rank gene Pg(10) statistic rank gene Pg(10) statistic rank gene Pg(10) statistic
1 93 1.00 0.900 1 93 1.00 0.090 1 93 1.00 0.971 1 93 1.00 6.149
2                
                
                
                
                
                
                
                
                
76 0.81 0.767 2 65 0.99 0.059 2 42 1.00 0.870 2 65 1.00 5.090
3 65 0.98 0.733 3 5 0.94 0.051 3 76 1.00 0.864 3 42 0.96 4.238
4 42 0.92 0.667 4 23 0.83 0.044 4 65 0.98 0.854 4 97 0.74 3.543
5 5 0.89 0.600 5 42 0.60 0.041 5 16 0.82 0.804 5 39 0.71 3.321
6.5 16 0.71 0.533 6 51 0.68 0.040 6 5 0.74 0.789 6 23 0.60 3.032
6.5 39 0.61 0.533 7 52 0.63 0.040 7 52 0.74 0.784 7 35 0.55 3.011
8 35 0.58 0.500 8 35 0.38 0.033 8 97 0.71 0.780 8 76 0.50 2.664
9.5 23 0.54 0.467 9 73 0.38 0.032 9 39 0.52 0.752 9 63 0.40 2.567
9.5 52 0.43 0.467 10 76 0.48 0.032 10 75 0.43 0.736 10 5 0.47 2.554
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Table 2 
Results of a simulation study with N=2000 genes of which 100 are informative about disease 
status. Shown are P[Rank(g)≤100] for informative genes. In all simulations Yg has a standard 
normal distribution among controls and for non-informative genes among cases. The distribution 
of Y for informative genes  is N(1,2) in setting A and N(1,1) in setting B. Dg
 A B 
 n=#cases=#controls n=#cases=#controls 
Statistic 15 25 35 15 25 35 
ROC(.10) .69 .82 .89 .57 .69 .77 
pAUC(.10
) 
.68 .83 .92 .50 .62 .72 
ROC(.20) .59 .75 .83 .65 .76 .84 
pAUC(.20
) 
.68 .83 .91 .58 .71 .81 
AUC .42 .56 .66 .68 .84 .92 
T statistic .42 .58 .68 .69 .84 .93 
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Table 3 
Study power Pg {100| ∈ k1} as a function of sample size using the ovarian cancer data as a 
simulation model. Also shown is the power for the more stringent criterion Pg {100| ∪ k1}. 
  Pg {100| ∈ k1} 
True Ranking (k1) ≤ 10 ≤ 20 ≤ 30 ≤ 40 ≤ 50 
 (nD, nc)      
 (15, 15) .997 .982 .934 .893 .850 
 (25, 25) 1.000 .996 .973 .949 .914 
 (50, 50) 1.000 1.000 .994 .987 .968 
 (100, 100) 1.000 1.000 .999 .998 .990 
  Pg {100| ∪ k1}. 
 (15, 15) .960 .654 .120 .016 .000 
 (25, 25) 1.000 .928 .486 .202 .024 
 (50, 50) 1.000 1.000 .836 .638 .206 
 (100, 100) 1.000 1.000 .984 .928 .608 
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